ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ABSK141

A development code. Also written as “ABSK141-400mg”, “ABSK141-Recommended Dose for Expansion (RDE)” and “ABSK141-800mg”.

Its studies are led by Abbisko Cayman.

Furthest: phase 2, since Jan 28, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Cayman11 open or runningphase 2since Jan 28, 2026Jan 28, 2026Dec 30, 2028phase 2 · NCT07417189

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 28, 2026First study: phase 2 study in Solid Tumors, AdultFirst studyNCT07417189 · 401 planned · China

Ahead

  1. Dec 30, 2028Primary completion: phase 2 study in Solid Tumors, AdultNCT07417189

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07417189Solid Tumors, Adult · China2RecruitingDec 30, 2028401

How it is read

Names in the registry

  • “ABSK141-400mg”, 1 entry
  • “ABSK141-Recommended Dose for Expansion (RDE)”, 1 entry
  • “ABSK141-800mg”, 1 entry
  • “ABSK141-1200mg”, 1 entry
  • “ABSK141-Recommended Phase 2 dose (RP2D)”, 1 entry

Codes read as this program: ABSK141.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.